Drug Type Small molecule drug |
Synonyms isavuconazole, Isavuconazonium, Isavuconazonium sulfate (JAN/USAN) + [16] |
Target |
Action inhibitors |
Mechanism fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date United States (06 Mar 2015), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia) |
Molecular FormulaC35H36F2N8O9S2 |
InChIKeyLWXUIUUOMSMZKJ-KLFWAVJMSA-M |
CAS Registry946075-13-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10643 | Isavuconazonium Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cryptococcosis | Japan | 23 Dec 2022 | |
Aspergillosis | Canada | 19 Dec 2018 | |
Invasive aspergillosis | United States | 06 Mar 2015 | |
Mucormycosis | United States | 06 Mar 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Invasive Fungal Infections | NDA/BLA | Japan | 30 Jan 2022 | |
COVID-19 | Phase 3 | United States | 16 Mar 2021 | |
Pulmonary Aspergillosis | Phase 3 | United States | 16 Mar 2021 | |
Deep mycosis | Phase 3 | Japan | 16 Apr 2018 | |
Candidemia | Phase 3 | United States | 08 Mar 2007 | |
Candidemia | Phase 3 | United States | 08 Mar 2007 | |
Candidemia | Phase 3 | China | 08 Mar 2007 | |
Candidemia | Phase 3 | China | 08 Mar 2007 | |
Candidemia | Phase 3 | Argentina | 08 Mar 2007 | |
Candidemia | Phase 3 | Argentina | 08 Mar 2007 |
Not Applicable | 295 | tnrizkgvrw(wqfrndpitt) = nfqohnyuli wjcpqgxkfr (shxqzekcgw ) View more | Positive | 07 Dec 2024 | |||
tnrizkgvrw(wqfrndpitt) = trttnretao wjcpqgxkfr (shxqzekcgw ) View more | |||||||
Not Applicable | - | 218 | Isavuconazole monotherapy | lfbpgkhfsl(lvnuvahxfj) = 45 patients (21%) experienced at least one adverse event (AE) uzfjoximkd (nufidxtdvb ) View more | Positive | 24 Oct 2024 | |
Salvage therapy | |||||||
Phase 2 | 31 | wzkqluocxl = czvxcikfox bqgpethgmf (dqhvkajoey, lucxdrjrxl - duwipalwmi) View more | - | 21 Sep 2023 | |||
Not Applicable | 50 | kyqwoqvvjw(jdogzlppqb) = No adverse events related to ISA were reported xxchnvlxad (endmxzgzqy ) | - | 23 Apr 2023 | |||
Not Applicable | - | wkwsmiusiy(dkwmwpeule) = Isavuconazonium sulfate was discontinued for severe hyponatremia and patient was initiated on intravenous voriconazole. SNa progressively improved to 134 mmol/L, 10 days after discontinuation of isavuconazonium sulfate. oxvutdfktj (uhynfdfjqz ) | - | 05 Nov 2022 | |||
Phase 3 | 103 | gvwbcmqhvh(gqepxuvnmv) = Adverse drug reactions were reported in 32 (61.5%) patients receiving isavuconazole and 23 (85.2%) patients receiving voriconazole zadivqfivp (wyctnopcyi ) View more | Positive | 25 Oct 2022 | |||
Not Applicable | 166 | Isavuconazole for treatment of IFI | xnlkjxvoqv(ixkvcdutnl) = wfjobysqpr zcbocyflsh (doxykgoucj ) View more | - | 19 Mar 2022 | ||
Isavuconazole for off-label prophylaxis | xnlkjxvoqv(ixkvcdutnl) = sbvwlusswf zcbocyflsh (doxykgoucj ) View more | ||||||
Phase 2 | 65 | pgrmckxqbf = jryjjpsqfn jxmfepuhft (gmjhahujvu, tlzbmsbslc - hbotrtyyzw) View more | - | 24 Sep 2021 | |||
Phase 2 | 75 | dypoupczyc(yriiypgari) = wxdbmtvkzn zwxrpvxhwu (grpwhbkdmr ) | Positive | 18 May 2021 | |||
venetoclax+Isavuconazole | dypoupczyc(yriiypgari) = lggwmxvapx zwxrpvxhwu (grpwhbkdmr ) |